Insulin Glargine in the Intensive Care Unit:
A Model-Based Clinical Trial Design

Jonathan G Willis[1], Liam Fisk[1], Normy Razak, Aaron Le Compte[1],
Geoffrey M Shaw[2], and J Geoffrey Chase[1*]

[1]Department of Mechanical Engineering, Centre for Bio-Engineering, University of Canterbury, Christchurch, Private Bag 4800, 8054, New Zealand

[2] Department of Intensive Care, Christchurch Hospital, Christchurch School of Medicine and Health Science, University of Otago, Christchurch, New Zealand

*Corresponding Author: geoff.chase@canterbury.ac.nz

Abstract

Introduction: Current succesful AGC (Accurate Glycemic Control) protocols require extra clinical effort and are impractical in less acute wards where patients are still susceptible to stress-induced hyperglycemia. Long-acting insulin Glargine has the potential to be used in a low effort controller. However, potential variability in efficacy and length of action, prevent direct in-hospital use in an AGC framework for less acute wards.

Method: Clinically validated virtual trials based on data from stable ICU patients from the SPRINT cohort who would be transferred to such an approach are used to develop a 24-hour AGC protocol robust to different Glargine potencies (1.0x, 1.5x and 2.0x regular insulin) and initial dose sizes (dose = total insulin over prior 12, 18 and 24 hours). Glycemic control in this period is provided only by varying nutritional inputs. Performance is assessed as %BG in the 4.0-8.0mmol/L band and safety by %BG<4.0mmol/L.

Results: The final protocol consisted of Glargine bolus size equal to insulin over the previous 18 hours. Compared to SPRINT there was a 6.9% - 9.5% absolute decrease in mild hypoglycemia (%BG<4.0mmol/L) and up to a 6.2% increase in %BG between 4.0 and 8.0mmol/L. When the efficacy is known (1.5x assumed) there were reductions of: 27% BG measurements, 59% insulin boluses, 67% nutrition changes, and 6.3% absolute in mild hypoglycemia.

Conclusion: A robust 24-48 clinical trial has been designed to safely investigate the efficacy and kinetics of Glargine as a first step towards developing a Glargine-based protocol for less acute wards. Ensuring robustness to variability in Glargine efficacy significantly affects the performance and safety that can be obtained.

1.0 Introduction

Critically ill patients often suffer stress induced hyperglycemia [1]. Hyperglycemia is associated with an increased risk of infection, myocardial infarction and mortality [2-4]. Attempting to control hyperglycemia can significantly increase the risk of hypoglycemia [5] making original promising results [6, 7] difficult to repeat [8-10]. The SPRINT glycemic control protocol [7] is the only published protocol to reduce both mortality and hypoglycemia. However, it requires BG measurements every 1 – 2 hours. Thus, the clinical effort required is high and may not be necessary for all patients.

It is common for patients to be admitted to a High Dependency Unit (HDU) if they are not intubated or do not require extensive circulatory support. There can be a reluctance to use AGC (Accurate Glycemic Control) protocols in the HDU due to the clinical effort and relatively limited nursing resources [11], leading to a tolerance of some hyperglycemia. However, these patients are still susceptible to counter-regulatory stress responses and hyperglycemia, necessitating an effective method to transition glycemic control from critical care to less acute wards with less nursing resources and less use of intravenous lines to deliver insulin or other drugs.

Glargine is a very long acting insulin analogue used to manage Type 1 diabetes, primarily in relatively low doses (per hour) to replace basal insulin. It is administered subcutaneously and released very slowly into the blood plasma over 22 – 26 hours [12]. Hence, it has potential advantages for a low intensity AGC protocol requiring only one daily administration.

Although many studies have been carried out on the specific kinetics and dynamics of Glargine in healthy individuals, there is still insufficient data for use with in-hospital AGC protocols on highly dynamic, critically ill patients. Current studies indicate that Glargine may be up to twice as potent as regular insulin [13], which, with varying kinetics and appearance rates [14], could add significant risk in using higher doses for these patients whose insulin sensitivity can vary significantly over time compared to healthy individuals [15].

Further clinical information about the dynamics of Glargine in these patients is required to avoid unnecessary risk. Model-based control and simulation environments can be used to develop clinical protocols to safely examine different expected action profiles and efficacy of Glargine in these patients, while simultaneously providing AGC. In particular, this study develops a first model-based controller to be used in 24 hour pilot trials to assess the potential of Glargine in this cohort, and to also collect data on the issues of efficacy and kinetics while producing safe, effective AGC in a replicable fashion. This is the first example to employ model-based control to elucidate specific drug properties.

2.0 Methods:

The SING (Stochastic Insulin Nutrition and Glargine) controller was developed using clinically validated virtual trials [16] on virtual patients based on retrospective clinical data. It combines the ICING (Intensive Control Insulin Nutrition Glucose) model [17] of insulin-glucose pharmacokinetics and pharmacodynamics and glucose disappearance in plasma with a validated model of subcutaneous pharmacokinetics of Glargine from injection to appearance in plasma [18-20] and makes use of the stochastic forecasting used in STAR [21].

2.1 ICING Model:

Five differential equations describe the glucose-insulin pharmacokinetics and pharmacodynamics in the plasma and interstitium with one state-dependent function:

$$\dot{G} = -p_G G(t) - S_I G(t)\frac{Q(t)}{1 + \alpha_G Q(t)} + \frac{\min(d_2 P_2, P_{max}) + EGP_b - CNS + PN(t)}{V_g} \quad (1)$$

$$\dot{I} = -\frac{n_L I(t)}{1 + \alpha_I I(t)} - n_K I(t) - n_I\big(I(t) - Q(t)\big) + \frac{u_{ex}(t)}{V_I} + (1 - x_L)\frac{u_{en}(G)}{V_I} \quad (2)$$

$$\dot{Q} = n_I\big(I(t) - Q(t)\big) - n_C\frac{Q(t)}{1 + \alpha_G Q(t)} \quad (3)$$

$$\dot{P_1} = -d_1 P_1 + P(t) \quad (4)$$

$$\dot{P_2} = -\min(d_2 P_2, P_{max}) + d_1 P_1 \quad (5)$$

$$u_{en}(G) = \max\left(16.67, \frac{14G(t)}{1 + 0.0147G(t)} - 41\right) \quad (6)$$

Where $G(t)$ [mmol/L] is the total plasma glucose, $I(t)$ [mU/L] is the plasma insulin and interstitial insulin is represented by $Q(t)$ [mU/L]. Exogenous insulin input is represented by $u_{ex}(t)$ [mU/min] and endogenous insulin production is estimated with u_{en} [mU/min], modelled as a function of plasma glucose concentration determined from critical care patients with a minimum pancreatic output of 1U/hr. P_1 [mmol] represents the glucose in the stomach and P_2 [mmol] represents glucose in the gut. Enteral glucose input is denoted $P(t)$ [mmol/min]. Table 1 shows the major components and constants of the model defined in Equations 1-5. A graphical overview is presented in Figure 1.

Table 1: Constants and identified parameter ranges in the ICING model of Equations 1 – 6

| Model variable	Numerical value (or typical range)	Definition
p_G	0.006 min^{-1}	endogenous glucose clearance
S_I	[1x10^{-7} – 1x10^{-2}] L/(mU.min)	insulin sensitivity
α_G	1/65 L/mU	saturation of insulin-dependent glucose clearance and receptor-bound insulin clearance from interstitium
d_1	-ln(0.5)/20	rate of glucose transfer between the stomach and gut
d_2	-ln(0.5)/100	rate of glucose transfer from the gut to the bloodstream
EGP_b	1.16 mmol/min typically	Basal endogenous glucose production (unsuppressed by glucose and insulin concentration)
CNS	0.3 mmol/min	non-insulin mediated glucose uptake by the central nervous system
V_G	13.3 L	glucose distribution volume
P_{max}	6.11 mmol/min	Maximum disposal rate from the gut
n_I, n_c	0.0075 min^{-1}	rate of transport between plasma and interstitial insulin compartments
α_I	1.7x10^{-3} L/mU	saturation of plasma insulin clearance by the liver
V_I	4.0 L	insulin distribution volume
x_L	0.67	First-pass hepatic insulin clearance
n_K	0.0542 min^{-1}	clearance of insulin from plasma via the renal route
n_L	0.1578 min^{-1}	clearance of insulin from plasma via the hepatic route

Figure 1: ICING model schematic overview

2.2 Glargine Compartment Model

The Glargine Compartment model captures the kinetics of Glargine from injection to appearance in plasma. Glargine has four states: precipitate, hexameric, monomeric / dimeric, and local interstitium. Figure 2 shows the interaction of these states [18, 19]. The resulting compartment model is defined:

Precipitate State

$$\dot{p}_{gla}(t) = \frac{-k_{prep,gla}p_{gla}(t)}{1 + \dfrac{k_{prep,gla}}{r_{dis,max}}p_{gla}(t)} + u_{p,gla}(t) \tag{7}$$

$$u_{p,gla}(t) = \alpha_{gla}u_{total,gla}(t) \tag{8}$$

Hexameric State

$$\dot{x}_{h,gla}(t) = -(k_{1,gla} + k_d)x_{h,gla}(t) + \frac{k_{prep,gla}p_{gla}(t)}{1 + \frac{k_{prep,gla}}{r_{dis,max}}p_{gla}(t)} \tag{9}$$

$$u_{h,gla}(t) = u_{total,gla}(t)(1 - \alpha_{gla}) - u_{m,gla}(t) \tag{10}$$

<u>Dimeric/Monomeric State</u>

$$\dot{x}_{dm}(t) = -(k_2 + k_d)x_{dm}(t) + k_{1,gla}x_{h,gla}(t) + u_{m,gla}(t) \qquad (11)$$

<u>Interstitium</u>

$$\dot{x}_i(t) = -(k_3 + k_{di})x_i(t) + k_2 x_{dm}(t) \qquad (12)$$

Where $p_{gla}(t)$ [mU] is the total Glargine in precipitate form, $x_{h,gla}(t)$ [mU] is the total Glargine in hexameric form, $x_{dm}(t)$ [mU] is the total Glargine in monomeric / dimeric form and $x_i(t)$ [mU] is the total Glargine in the (local) interstitium. The exogenous Glargine is represented by $u_{p,gla}(t)$ [mU] in the precipitate form, $u_{m,gla}(t)$ in the monomeric / dimeric form and $u_{h,gla}(t)$ in the hexameric form. All other terms and values are defined in Table 2, based on an extensive validation study [18, 19].


Figure 2: Glargine Compartment Model Overview

Table 2: Constants and definitions in the Glargine compartment model

Model Variable	Numerical Value		Description
$k_{prep,gla}$	0.0216	[min^{-1}]	Glargine precipitate dissolution rate
$alpha_{gla}$	0.9462		Fraction of glargine as precipitate
$k_{1,gla}$	0.0062	[min^{-1}]	Hexamer dissociation rate
D	9.00x10^{-5}	[cm^2/min]	Diffusion constant for hexameric and dimeric/monomeric states
k_2	0.0106	[min^{-1}]	Dimeric/monomeric insulin transport rate into interstitium
k_3	0.0618	[min^{-1}]	Interstitium transport rate into plasma
k_{di}	0.029	[min^{-1}]	Rate of loss from interstitium
V_x	11.38	[L]	Subcutaneous insulin distribution volume
B_{r_dismax}	2.3134	[mU/min]	Baseline glargine precipitate dissolution rate
Q_D	1.50x10^{-2}	[ml^2/mU^2]	Hexameric–dimeric equilibrium constant
U_{tres}	2.01x10^3	[mU]	Dosage threshold

Glargine release from precipitate to hexameric form is a saturable process. The maximum dissolution rate, $r_{dis,max}$ [mU/min], gives Glargine its unique kinetic profile and is defined:

$$r_{dis,max} = Br_{dis,max}(\alpha_{gla}u_{total,gla} < U_{tres}) + \frac{Br_{dis,max}\alpha_{gla}u_{total,gla}}{U_{tres}}(\alpha_{gla}u_{total,gla} \geq U_{tres}) \quad (13)$$

where $Br_{dis,max}$ [mU/min] is the baseline precipitate dissolution rate and U_{tres} [mU] is the dosage threshold. The volume of the Glargine injected also has an effect on the kinetics in the form of a diffusive loss from the hexameric and monomeric /dimeric states. The rate of this diffusive loss k_d [min^{-1}] is defined:

$$k_d = \frac{3D}{r} \quad (14)$$

$$r = \left(\frac{3V_{inj}}{4\pi}\right)^{1/3} \quad (15)$$

where r [cm] is the radius of the depot formed by the subcutaneous injection and D [cm^2/min] is the diffusion constant for the hexameric and monomeric /dimeric states.

Finally the initial quantity of the Dimeric/Monomeric state in solution is found by solving the following derived from [19]:

$$Q_D V_{inj} \left(\frac{U_m}{V_{inj}} \right)^3 + u_m - u_{total}(1 - \alpha_{gla}) = 0 \qquad (16)$$

2.3 Control Approach

The main goal is to develop a robust and safe controller to investigate the efficacy and variability in Glargine kinetics, without degrading control quality or safety from hypoglycemia. The main issues are the potential variation in Glargine efficacy (1.0-2.0x), the periods of low insulin appearance at the start and end of Glargine's 22-26 hour action period, and the need to modulate nutrition rates during Glargine administration for safety and performance because insulin administration is determined solely by Glargine appearance.

There is evidence suggesting that Glargine may be to be up to 2 times as effective as regular insulin, partly attributed to a more effective bonding to the IGF-I receptor [22]. Hence, this study assumes an estimated Glargine efficacy factor of 1.5 for design, in the absence of other data. Each resulting controller was then tested with efficacy factors of 1.0, 1.5 and 2.0. If a controller provided a satisfactory level of control for all three efficacies then it was deemed safe and robust to this variable.

Although Glargine has a relatively flat action profile that acts over a 22-26 hour period [23], 3-6 hours is required before a significant appearance of insulin is observed in plasma, resulting in a period of low insulin appearance immediately after Glargine is administered. A

similar phenomenon occurs at the end of the 22-26 hour period. For this trial design, the STAR protocol [21] is assumed running during the first and last 4 or 6 hours of the estimated 24-hour period after Glargine is administered to supplement Glargine appearance with IV insulin, as it is the current standard of care in Christchurch Hospital.

To best observe the effects of Glargine, a period of Glargine as the only exogenous insulin is desired to eliminate other factors. However, longer periods increase the potential for control degradation. During the 16-hour peak of Glargine action, no exogenous insulin is administered, during which glycemic control is achieved only by modulating nutrition administration rates. The results will allow determination of Glargine efficacy and kinetics for each patient, and thus their variability across a test cohort.

BG measurements are intended to be taken hourly during the 24-hour trials to ensure safety. However, for in-silico virtual trials, 2 and 3-hourly BG measurements are used for the Glargine isolation period to illustrate the potential to reduce clinical effort.

Glargine bolus size was based on the total insulin previously administered to the patient, as a simple and easily calculated bedside metric. The sum over the previous 12, 18 and 24 hours before the Glargine is administered was tested. Values less than the 24-hour sum reflect both safety concerns over efficacy, as well as the tendency for stable patients to improve and require increasingly less insulin [15].

STAR [21] targets a forecasted 5th and 95th percentile glucose values to specified BG ranges. During the 16 hour Glargine isolation period this BG target places the 95th percentile BG outcome on 8 mmol/L, otherwise the 5th is placed on 4.4mmol/L. Figure 3 illustrates the stochastic bands used by STAR when recommending treatments. A, B, and C show the 5th percentile of BG values for a given intervention and D, E, and F show the 95th percentile BG value, for 1, 2 and 3-hourly predictions.

The lower BG target is 4.4 mmol/L with an upper tolerance of 1mmol/L when a 5th percentile BG outcome to low bound target is used. The upper BG target is 8.0 mmol/L with an upper tolerance of 1mmol/L when a 95th percentile BG outcome to high bound target is used in the Glargine isolation period. The tight control achieved with SPRINT (the standard protocol in the Christchurch ICU) is not expected with the SING controller due to the decreased interventions in the Glargine isolation period. Therefore, the large tolerance bands are chosen to ensure higher nutrition rates and loosen regulation for these less acute, stable wards.


Figure 3: Schematic of control using stochastic forecasting showing a typical BG profile and 1-3 hour forecast BG bands. Target range of 4.4-8.0 mmol/L is shown with the 1mmol/L tolerances used in the different controllers.

The controller logic for targeting the 95th percentile BG outcome is shown in Figure 4. It calculates the patient outcomes for nutrition at the highest allowed nutrition rate and attempts to target the 95th percentile of BG outcomes to the upper target band. A check is made to ensure that the 5th percentile of BG outcomes does not drop below the lower band. If an acceptable treatment is not found, the nutrition rate is reduced and the logic re-applied. For the in-silico virtual trials, 2 and 3 hourly measurements are permitted by running the logic in Figure 4 with 1, 2 and 3-hourly forecasts. Note that only nutrition can be modulated in this period to control glycemia once Glargine is given. Similar logic is used for the 5th percentile controller.


Figure 4: Controller logic. It modulates nutrition only and assumes insulin appearance based on the models of Equations 1-6 and 7-16

The clinical trial design consists of:

- Glargine administered based on patient's previous insulin requirements

- STAR recommended insulin boluses administered on top of the Glargine at the start and end of the action profile. The 5th percentile BG outcome to low bound target is used in this period.

- No exogenous IV insulin is recommended during the 16-hour peak Glargine appearance, 95th percentile BG outcome to high bound target is used.

- BG measurements hourly for safety

Finally, a second controller, SING2, is designed specifically to demonstrate the potential reductions in effort if the efficacy of Glargine is known so that a more aggressive and lower clinical effort control method can be implemented safely. The SING2 controller's logic in this specific case is defined:

- Assumes Glargine efficacy of 1.5x

- Glargine bolus size equal to the insulin administered over the previous 24 hours

- STAR recommended boluses on top of Glargine for all 24-hours

- 2 and 3 hourly treatments permitted per STAR [21]

- 95th percentile BG outcome is targeted to the high bound

- The upper tolerance band on the upper target is 1 mmol/L

2.4 Virtual Trials

Clinically validated virtual trials [16] were run on virtual patients made from retrospective clinical data. The virtual patients were created using the clinical data to create hourly insulin

sensitivity profiles which are used to simulate the effects of different treatments on the patients.

The following virtual trials were run on the virtual patient cohort. Simulation outcomes for the 24 hour trials were used to verify performance both directly against SPRINT.

- Glargine bolus size equal to total insulin recommendations over the previous 12, 18 and 24 hours. Each run at 1.0, 1.5 and 2.0x efficacy with 95th BG outcome targeted to the high bound during a Glargine isolation period of 16 hours

- Best performing Glargine bolus size with a Glargine isolation period of 12 hours at 1.0, 1.5 and 2.0x efficacy with 95th BG percentile to high bound targeting during the isolation period

- Best performing controller logic with 5th BG percentile to low bound targeting throughout

- Glargine bolus size equal to total insulin recommendations over the previous 12, 18 and 24 hours at 1.5 efficacy with no Glargine isolation period and 95th BG percentile to high bound targeting throughout

The outcomes are used to determine the most robust and safest dose and control response.

2.5 Performance Metrics

Results from the clinically validated in-silico virtual trials are compared to the original SPRINT clinical data to assess safety and performance. An overall increase in BG levels is expected as a result of decreased clinical intervention without increasing the risk of hypoglycemia. The performance of each controller was assessed by the following criteria:

1. **Effort:** Number of nursing interventions from nutrition rate changes, insulin boluses and BG measurements

2. **Performance:** Measuring the percentage of BG between 4.0 and 8.0 mmol/L

3. **Nutrition:** Enteral nutrition administration rates as a percentage of ACCP/SCCM goal rates [24]

4. **Safety:** Percentage of BG less than 4.0mmol/L

It is important to note that the figures for the number of BG measurements for the SING controller do not include those extra measurements taken hourly only for safety in planned clinical trials being designed.

2.6 Virtual Patients

The target patients for these trials are critically ill, but in a relatively stable state. Seventeen (of 391) patients from the SPRINT cohort [7] met the following stability criteria:

- Stable hourly insulin requirement of $\leq$ 3U/hr of insulin, for at least 12 hours

- Stable nutrition rate of $\geq$ 60% of the calculated individual patient's goal rate, based on ACCP guidelines of 25kcal/kg/hr [24]

- No acute renal failure

- Less than 1000ml of fluid given as intravenous boluses in the past 24 hours, indicating hemodynamic or circulatory stability and a stable interstitial volume.

- Resolving multiple organ failure based on a Sequential Organ Failure Assessment (SOFA) score < 6 [25]

For safety and to limit Glargine bolus size in this initial study an additional criterion was:

- Maximum total insulin requirement of $\leq$ 48U, over the last 18 hours

These criteria define a set of patients who would be eligible for transfer to a HDU and a less intense AGC routine. The number (17) is low enough to create an initial protocol without excessive data, and other patients (of 391) might readily qualify. The total insulin dose criterion, chosen also for safety in planned clinical trials to limit dose, was a significant limiting factor for patient numbers. Table 3 presents the demographic details of the 17 patients.

Table 3: Patient Cohort

Patient ID	LOS (hrs)	Medical Group	Apache II score	Age (years)	Sex	Mortality
5006	161	Respiratory Failure	23	44	F	N
5033	100	Trauma	29	66	F	N
5054	158	Respiratory Failure	18	75	M	N
5060	271	Gastrointestinal	15	79	M	N
5061	140	Trauma	16	22	M	N
5076	240	Gastrointestinal	12	32	M	N
5086	127	Respiratory	32	64	M	N
5101	280	Neurological	19	50	F	N
5122	159	Trauma	19	73	M	N
5149	325	Surgical	21	60	M	N
5207	155	Respiratory	19	42	F	N
5279	85	Septic Shock	18	18	M	N
5299	103	Respiratory	20	56	F	N
5315	196	Respiratory	18	19	M	N
5322	136	Respiratory	15	72	F	N
5351	166	Respiratory	12	76	M	N
5376	120	Surgical	16	56	F	N
Median	158		18	56	58%	
IQR	[127 - 196]		[16 - 20]	[42 - 72]	Male	

3.0 Results

Table 4 shows the expected glycemic differences between Glargine dose sizes for the nominal 1.5x efficacy. The sum over 18 hours was selected due to the safety limits imposed on the Glargine dosage, and it showed a balance of %BG within the 4.0 − 8.0 mmol/L band and %BG < 4.0 mmol/L, comparable to or better than SPRINT. While this choice reduced the number of nutrition changes required to maintain control using Glargine, it is evident that the fixed insulin dose requires greater nutrition adjustment compared to SPRINT, which used both in control.

Table 4: Comparison of SING with dosage based on 12, 18 and 24 hours at 1.5x efficacy with STAR used for the first and last 4 hours

	12 hour sum	18 hour sum	24 hour sum	SPRINT
BG measurements	258	260	266	267
Boluses administered	112	113	112	311
Nutrition changes	96	90	103	39
% BG within 4.0 - 8.0 mmol/L	91.29	92.71	94.59	88.60
Median glucose rate (%goal)	100%	100%	100%	90%
% BG < 4.0 mmol/L	1.41	2.35	4.71	11.16
Median Glargine Dose (U) [min max]	18.0 [6.0 - 30.0]	24.0 [6.0 - 48.0]	36.0 [6.0 - 72.0]	N/A

Table 5 shows a comparison at 1.5x efficacy for STAR running for the first and last 4 or 6 hours of the 24 hours after Glargine is administered, as well as a comparison between if a 5th percentile or 95th percentile based targeting system is used. For a 4-hour STAR period (16h Glargine isolation) there was slightly poorer control compared to the 6-hour STAR period (12h Glargine isolation). However, the 4-hour STAR period still outperformed SPRINT and reduced mild hypoglycemia compared to the 6-hour STAR period. During the 16 hour Glargine isolation period there was a tendency for the controller to recommend lower nutrition rates for a 5th percentile BG outcome to low bound targeting system. Hence a 95th

percentile BG outcome to high bound target was selected to meet clinical preferences for higher nutrition rates.

Table 5: Comparison of SING with 5th percentile BG outcome to low bound and 95th percentile to high bound and 4 hour and 6 hour STAR periods at 1.5x efficacy

	SPRINT	4 hour STAR period, 95th percentile to high bound	6 hour STAR period, 95th percentile to high bound	4 hour STAR period, 5th percentile to low bound
BG measurements	267	260	307	257
Boluses administered	311	113	167	111
Nutrition changes	39	90	80	116
% BG within 4.0 - 8.0 mmol/L	88.60	92.71	94.59	95.06
Median glucose rate (%goal)	90%	100%	100%	70%
% BG < 4.0 mmol/L	11.16	2.35	4.00	3.06

Based on these results, the final recommended SING controller comprises:

- Glargine bolus size equal to the insulin administered over the previous 18 hours

- STAR recommended boluses used for the first and last 4 hours of the 24 hour period after Glargine has been administered, 1 hour treatments only during this period.

- During the period where Glargine is the only form of exogenous insulin, the 95th percentile BG outcome is targeted to the high bound, all other times the 5th percentile BG outcome is targeted to the low bound

- The upper tolerance on the upper BG target is 1 mmol/L

- Recommendations are made on the basis of a Glargine efficacy factor of 1.5 times

- Recommended dosage is rounded to the nearest 6U for clinical convenience

Table 6 shows the final SING controller compared against SPRINT with varying efficacy levels. Figure 5 shows how BG varies for a representative patient for the 24-hour trial after an initial Glargine dose of 18U. The varying efficacy and the relatively linear relation between BG and insulin efficiency is observed as expected. Safety was not compromised.

Table 6: Final SING Controller

|	SPRINT	SING		
Efficacy:	-	1.0x	1.5x	2.0x
BG measurements	267	269	260	254
Boluses administered	311	114	113	110
Nutrition changes	39	98	90	78
% BG within 4.0 - 8.0 mmol/L	88.60	87.76	92.71	94.12
Median glucose rate (% goal)	90%	100%	100%	100%
% BG < 4.0 mmol/L	11.16	1.65	2.35	4.24

Figure 5: Patient 5299 - Effects of Efficacy

The median nutrition rate is 100% of goal rate regardless of efficacy. The results show that adequate control is achieved for the case where Glargine is no more potent than regular insulin and control is improved for higher potencies of Glargine. However, for a higher potency, the risk of mild hypoglycemia increases, but even at the maximum suspected potency (2.0x) there is still a significant improvement over the SPRINT protocol. The cumulative frequency of BG levels in Figure 6 clearly shows robustness with a good balance of safety and performance. There is a significant reduction in %BG < 4.4 mmol/L, and the relatively steep CDF slopes indicate the BG variability remains tightly controlled.


Figure 6: BG cumulative frequency for SING and SPRINT for all patients

The controller has been shown to be robust with perturbations made to the initial Glargine bolus size, based on prior insulin requirements. The results from altering the length of time that Glargine bolus sizes are based on show that, at worst (1.0x efficacy based on insulin requirements over 12 hours), control within the target band is 84.0%. Safety is improved by using 1-hourly STAR treatments in conjunction with Glargine in the first and last 4-hours.

The tight control achieved by the hourly STAR treatments has been proven to effectively control BG levels. Any unknown effects of Glargine will be compensated for with the model calculated insulin sensitivity. The small variance between the bands for varying efficacies in Figure 6 further indicates the robustness.

Table 7 shows an example the results from the SING2 controller, where it is assumed the efficacy is known to be 1.5. SING2 offers improved performance over SPRINT with increased nutrition delivery, patient safety, and time in desired band. A significant reduction in clinical effort is observed with a 27% reduction in BG measurements, a 59% reduction in insulin boluses and a 67% decrease in the number of nutrition changes required. Hence, if the efficacy is known reliably, then significant clinical effort reductions can be obtained with good performance and safety.

Table 7: SING2 for known Efficacy

	SPRINT	SING2	Δ%
BG measurements	267	196	-27%
Boluses administered	311	129	-59%
Nutrition changes	39	13	-67%
% BG within 4.0 - 8.0 mmol/L	88.6	92.66	+4.1% absolute
Median glucose rate (% goal)	90%	100%	+10% absolute
% BG < 4.0 mmol/L	11.16	4.82	-6.3% absolute

4.0 Discussion:

The simulation results for the SING controller and its variations show that it is a robust and safe initial protocol to investigate the safety and performance of Glargine in this cohort to reduce clinical effort and transition stable patients to subcutaneous delivery. A possible limitation of this study is the low number of virtual patients included in the cohort. SPRINT is used on a cohort from which such patients may come, but initial selection criteria may have been too strict. However, the cohort selected does fairly represent a combination of genders, medical conditions and age. A larger cohort of suitable patients, preferably in clinical testing, would enable a greater statistical validity of the results. However the results presented justify clinical testing to prove the concept.

The unknown efficacy of Glargine requires specific measures to reduce patient risk in these trials. Hence, a noticeable decrease in clinical effort is not observed for SING in these proposed trials. Even though there is a significant reduction in insulin boluses administered there is a significant increase in the number of nutrition changes required. However, the SING2 controller showed the potential reductions available if the efficacy is more reliably known. Highly patient-specific or variable efficacy discovered in the clinical trials designed here would thus create significant issues affecting the feasibility of using Glargine consistently in large cohorts of this type if reduction of effort is a major criterion.

In long term applications of Glargine over multiple days the periods of low insulin appearance in plasma during the Glargine's action will not be an issue if the kinetics and efficacy of Glargine is known. A protocol can be designed such that the Glargine profiles

overlap to minimise periods of low insulin appearance. This outcome is achieved by administering smaller doses more frequently than 24 hours.

A limitation of this trial design is that the effect of Glargine build up over days is not observed. Build up can occur if Glargine is present for more than 24 hours [26]. Simulation results for a single isolated dose of Glargine suggested that the build up of Glargine in the interstitial insulin compartment was not a significant issue. However, this behaviour has been observed clinically and may still play a role. The increase in interstitial insulin concentration was 4.6% of the initial value after 24 hours and 2.5% after 26 hours. Hence, over several days, this issue may not be a major factor given measurement and other errors that also contribute to the overall variation in control.

Finally, the goal of the controller was to investigate the kinetics and dynamics of Glargine. It is likely this information will be achieved through analysis of model-based S_I as the patient transitions to/from the Glargine only period. If (for example) SI shows a general increase or decrease over the Glargine period that is resolved with the reintroduction of IV insulin it would infer values for Glargine potency. During the Glargine only period nutrition rates may be modified.

5.0 Conclusions

This paper presents an investigation into the use of Glargine in AGC for low effort controllers. A robust clinical trial has been designed to safely investigate the efficacy and kinetics of Glargine, prior to developing a final protocol. If the results of this trial verify the efficacy and kinetics of Glargine in critically ill patients, a low effort controller can be implemented to extend AGC to the HDU. It remains for clinical testing to determine inter- and intra- patient variability, thus determining the overall potential for using Glargine in large cohorts of HDU patients and stable ICU patients.

Overall, the results demonstrate the concept and potential to justify pilot clinical trials. Equally they clearly and safely highlight, in-silico, some issues with subcutaneous long acting insulin that may not otherwise have arisen until clinical testing. Hence, these outcomes should be prospectively tested.

6.0 References

1. Capes SE, Hunt D, Malmberg K, Gerstein HC: **Stress hyperglycemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview**. *Lancet* 2000, **355**(9206):773-778.
2. Krinsley JS: **Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients**. *Mayo Clin Proc* 2003a, **78**(12):1471-1478.
3. Ousman Y: **Hyperglycemia in the Hospitalized Patient**. *Clinical Diabetes* 2002, **20**(3):147-148.
4. Marfella R, Siniscalchi M, Esposito K, Sellitto A, De Fanis U, Romano C, Portoghese M, Siciliano S, Nappo F, Sasso FC *et al*: **Effects of stress hyperglycemia on acute myocardial infarction: role of inflammatory immune process in functional cardiac outcome**. *Diabetes Care* 2003, **26**(11):3129-3135.
5. Griesdale DE, de Souza RJ, van Dam RM, Heyland DK, Cook DJ, Malhotra A, Dhaliwal R, Henderson WR, Chittock DR, Finfer S *et al*: **Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data**. *CMAJ* 2009, **180**(8):821-827.
6. Krinsley JS: **Decreased mortality of critically ill patients with the use of an intensive glycemic management protocol**. *Crit Care Med* 2003b, **31**:A19.
7. Chase JG, Shaw G, Le Compte A, Lonergan T, Willacy M, Wong X-W, Lin J, Lotz T, Lee D, Hann C: **Implementation and evaluation of the SPRINT protocol for tight glycemic control in critically ill patients: a clinical practice change**. *Critical Care* 2008, **12**(2):R49.
8. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S *et al*: **Intensive insulin therapy and pentastarch resuscitation in severe sepsis**. *N Engl J Med* 2008, **358**(2):125-139.
9. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR *et al*: **Intensive versus conventional glucose control in critically ill patients**. *N Engl J Med* 2009, **360**(13):1283-1297.
10. Preiser JC, Devos P: **Clinical experience with tight glucose control by intensive insulin therapy**. *Crit Care Med* 2007, **35**(9 Suppl):S503-507.
11. Aragon D: **Evaluation of nursing work effort and perceptions about blood glucose testing in tight glycemic control**. *Am J Crit Care* 2006, **15**(4):370-377.
12. Campbell RK, White JR, Levien T, Baker D: **Insulin glargine**. *Clinical Therapeutics* 2001, **23**(12):1938-1957.
13. Schmeltz LR, DeSantis AJ, Schmidt K, O'Shea-Mahler E, Rhee C, Brandt S, Peterson S, Molitch ME: **Conversion of intravenous insulin infusions to subcutaneously administered insulin glargine in patients with hyperglycemia**. *Endocr Pract* 2006, **12**(6):641-650.
14. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T: **Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo**. *Diabetes Care* 2000, **23**(5):644-649.
15. Chase JG, Le Compte AJ, Suhaimi F, Shaw GM, Lynn A, Lin J, Pretty CG, Razak N, Parente JD, Hann CE *et al*: **Tight glycemic control in critical care - The leading role of insulin sensitivity and patient variability: A review and model-based analysis**. *Computer Methods and Programs in Biomedicine* 2011, **102**(2):156-171.
16. Chase JG, Suhaimi F, Penning S, Preiser JC, Le Compte AJ, Lin J, Pretty CG, Shaw GM, Moorhead KT, Desaive T: **Validation of a model-based virtual trials method for tight glycemic control in intensive care**. *Biomed Eng Online* 2010, **9**:84.
17. Lin J, Razak, N., Pretty, C., Le Compte, A., Docherty, P., Parente, J., Shaw, G., Hann, C., and Chase, J.: **A physiological intensive control insulin-nutrition-glucose (icing) model validated in critically ill patients**. *Computer Methods and Program in Biomedicine* 2010.

18. Wong X, Chase J, Hann C, Shaw G, Lotz T, Lin J, Le Compte A: **A Subcutaneous Insulin Pharmacokinetic Model for Computer Simulation in a Diabetes Decision Support Role: Validation and Simulation**. *Journal of Diabetes Science and Technology (JoDST)* 2008b, **2**(4):672-680.
19. Wong X, Chase J, Hann C, Shaw G, Lotz T, Lin J, Le Compte A: **A Subcutaneous Insulin Pharmacokinetic Model for Computer Simulation in a Diabetes Decision Support Role: Model Structure and Parameter Identification**. *Journal of Diabetes Science and Technology (JoDST)* 2008a, **2**(4):658-671.
20. Razak N: **Robust Modelling of the Glucose-Insulin System for Tight Glycemic Control of Less Critical Care Patients**. *PhD thesis.* University of Canterbury; 2011.
21. Evans A, Shaw GM, Compte AL, Tan C-S, Ward L, Steel J, Pretty CG, Pfeifer L, Penning S, Suhaimi F *et al*: **Pilot proof of concept clinical trials of Stochastic Targeted (STAR) glycemic control**. *Annals of Intensive Care* 2011, **1**(38).
22. Varewijck AJ, Goudzwaard JA, Brugts MP, Lamberts SW, Hofland LJ, Janssen JA: **Insulin glargine is more potent in activating the human IGF-I receptor than human insulin and insulin detemir**. *Growth Horm IGF Res* 2010, **20**(6):427-431.
23. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB: **Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro**. *Diabetes* 2000, **49**(12):2142-2148.
24. Cerra FB, Benitez MR, Blackburn GL, Irwin RS, Jeejeebhoy K, Katz DP, Pingleton SK, Pomposelli J, Rombeau JL, Shronts E *et al*: **Applied nutrition in ICU patients. A consensus statement of the American College of Chest Physicians**. *Chest* 1997, **111**(3):769-778.
25. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG: **The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine**. *Intensive Care Med* 1996, **22**(7):707-710.
26. Lin J, Razak N, Chase JG, Wong J, Pretty C, Parente J, Le Compte A, Suhaimi F, Shaw G, Hann C: **The Effect of Glargine as Basal Insulin Support for Recovering Critically Ill and High Dependency Unit Patients: An In-silico Study**. In: *7th IFAC Symposium on Modelling in Control in Biomedical Systems: 2009; Aalborg, Denmark*; 2009.